cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Lucid Diagnostics Inc
5 own
11 watching
Current Price
$0.8
$0
(-0.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
54.84M
52-Week High
52-Week High
1.85000
52-Week Low
52-Week Low
0.76400
Average Volume
Average Volume
0.12M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization54.84M
icon52-Week High1.85000
icon52-Week Low0.76400
iconAverage Volume0.12M
iconDividend Yield--
iconP/E Ratio--
What does the Lucid Diagnostics Inc do?
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, a esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Read More
How much money does Lucid Diagnostics Inc make?
News & Events about Lucid Diagnostics Inc.
PR Newswire
11 months ago
PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023 PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023 PR Newswire NEW YORK, May 5, 2023 Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, May 5, 2023 /PRNewswire...
PR Newswire
11 months ago
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023 Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023 PR Newswire NEW YORK, May 5, 2023 Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, May 5, 2023...
PR Newswire
1 year ago
PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS PR...
PR Newswire
1 year ago
Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference PR Newswire NEW YORK, April 17, 2023 NEW YORK, April 17, 2023 /PRNewswire/ -- Lucid Diagnostics Inc.(Nasdaq: LUCD)('Lucid' or...
PR Newswire
1 year ago
Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular...
Frequently Asked Questions
Frequently Asked Questions
What is Lucid Diagnostics Inc share price today?
plus_minus_icon
Can Indians buy Lucid Diagnostics Inc shares?
plus_minus_icon
How can I buy Lucid Diagnostics Inc shares from India?
plus_minus_icon
Can Fractional shares of Lucid Diagnostics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Lucid Diagnostics Inc stocks?
plus_minus_icon
What is today’s traded volume of Lucid Diagnostics Inc?
plus_minus_icon
What is today’s market capitalisation of Lucid Diagnostics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Lucid Diagnostics Inc?
plus_minus_icon
What percentage is Lucid Diagnostics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Lucid Diagnostics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.8
$0
(-0.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00